<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00944008</url>
  </required_header>
  <id_info>
    <org_study_id>PRODECYTE</org_study_id>
    <nct_id>NCT00944008</nct_id>
  </id_info>
  <brief_title>PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Acute Lymphoblastic Leukemia</brief_title>
  <acronym>2009-009422-92</acronym>
  <official_title>PROCEDYTE: An Open, Prospective, Multicentre Clinical Trial With Historic Control to Determine Efficacy and Safety of Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration of Patients Between 16 and 30 Years Old With Standard Risk Acute Lymphoblastic Leukemia (ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PETHEMA Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PETHEMA Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is:&#xD;
&#xD;
        -  To determine the efficacy and safety of DepoCyte®, as the only intrathecal (IT)&#xD;
           prophylaxis of neuromeningeal relapse for patients between 16 and 30 years old diagnosed&#xD;
           with acute lymphoblastic leukemia of standard risk treated with the PETHEMA LAL-RI-08&#xD;
           Protocol Chemotherapy schedule.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To evaluate the tolerability of IT DepoCyte® as CNS prophylaxis of CNS via IT for&#xD;
           patients between 16 and 30 years old with ALL of standard risk.&#xD;
&#xD;
        -  To compare the frequency of relapse in CNS for patients between 16 and 30 years old with&#xD;
           standard risk ALL treated with the PETHEMA LAL-RI-08 Protocol Chemotherapy schedule and&#xD;
           receiving DepoCyte® as the only IT CNS prophylaxis, with that observed in an historic&#xD;
           group of patients of identical risk that were treated with the PETHEMA LAL-RI/96&#xD;
           protocol (same systemic chemotherapy and double administration of triple intrathecal&#xD;
           chemotherapy)&#xD;
&#xD;
        -  To evaluate the frequency of systemic relapses of standard risk ALL patients between 16&#xD;
           and 30 years old treated with the PETHEMA LAL-RI-08 Protocol and who receive DepoCyte®&#xD;
           as the only IT prophylaxis of CNS involvement and to compare with those observed in the&#xD;
           identical risk patients treated with PETHEMA LAL-RI/96 protocol (same systemic&#xD;
           chemotherapy and double administration of triple IT chemotherapy)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 85 patients between 16 and 30 years old with ALL of standard risk will be included&#xD;
      in the study. The aim of this study is to determine the efficacy and safety of the&#xD;
      administration of DepoCyte® as the only IT prophylaxis of the neuromeningeal relapse in&#xD;
      patients between 16 and 30 years old diagnosed with ALL of standard risk.&#xD;
&#xD;
      The study is divided in:&#xD;
&#xD;
      Screening: 2 weeks before treatment Treatment: 2 years of systemic treatment according to&#xD;
      PETHEMA LAL-RI-08 Protocol (Induction, Consolidation 1 and 2, Maintenance-1 with reinductions&#xD;
      and maintenance 2 with no reinductions). Patients will receive DepoCyte® in Induction,&#xD;
      Consolidation 1 and 2 and Maintenance 1 (first year). Patients will not receive DepoCyte® in&#xD;
      Maintenance-2 (second year).&#xD;
&#xD;
      Follow-up: Patients in the study will be followed up for one year&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy and safety of DepoCyte®, as the only intrathecal (IT) prophylaxis of neuromeningeal relapse</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability of IT DepoCyte</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the frequency of relapse in CNS with an historic group of patients of identical risk that were treated with the PETHEMA LAL-RI/96 protocol</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>Depocyte</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DepoCyte</intervention_name>
    <arm_group_label>Depocyte</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  According to the investigator opinion, patient must able to carry out with all the&#xD;
             clinical trial requirements&#xD;
&#xD;
          -  Patient or Legal Representative must volunteer sign the inform consent before any&#xD;
             study specific test, that is not part of the common patient attention, is performed.&#xD;
&#xD;
          -  Age 16 to 30&#xD;
&#xD;
          -  Patient diagnosed with standard risk ALL no previously treated. Standard risk ALL is&#xD;
             defined by the following criteria:&#xD;
&#xD;
          -  Leukocyte count &lt; 25x109/L&#xD;
&#xD;
          -  Absence of poor prognosis cytogenetic abnormalities:&#xD;
&#xD;
             t(9;22) or demonstration of BCR-ABL rearrangements. 11q23 alterations or demonstration&#xD;
             of ALL1-AF4 rearrangements.&#xD;
&#xD;
          -  Childbearing women must have a negative pregnancy test and must accept to use an&#xD;
             effective contraception method.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  CNS involvement at diagnosis, defined as presence of blasts in a centrifugated sample&#xD;
             of craneospinal fluid with a cellular count of more than 5 cels/L, in the absence of&#xD;
             traumatic puncture (more than 10 red blood cels/ml), or as neurological symptoms that&#xD;
             suggest of neuromeningeal involvement and imaging tests compatible, in the absence of&#xD;
             blasts in craneospinal fluid.&#xD;
&#xD;
          -  B mature cell phenotype (sIg+) or with the Burkitt ALL cytogenetic abnormalities&#xD;
             (t[8;14], t[2;8], t[8;22])&#xD;
&#xD;
          -  ALL with t(9;22) or BCR-ABL rearrangements.&#xD;
&#xD;
          -  Acute biphenotypic and bilineal leukemias&#xD;
&#xD;
          -  Acute undifferentiated leukemia&#xD;
&#xD;
          -  History of coronary or valvular disease or hypertensive cardiopathy&#xD;
&#xD;
          -  Chronic hepatopathy&#xD;
&#xD;
          -  Chronic respiratory insufficiency&#xD;
&#xD;
          -  Chronic renal insufficiency not due to ALL&#xD;
&#xD;
          -  Serious neurological disorders not due to ALL&#xD;
&#xD;
          -  Abnormal ECOG (WHO scale grade 3 and 4) not done by ALL&#xD;
&#xD;
          -  Pregnant or currently breast feeding women&#xD;
&#xD;
          -  Patients participating in other clinical trial or receiving any other investigational&#xD;
             agent within 30 days previous to the study inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sancho Jose Manuel, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hoapital General</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Meseguer.</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Carlos Haya.</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Dureta.</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario</name>
      <address>
        <city>Salamanca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío.</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital clínico Universitario</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://aehh.org</url>
    <description>Spanish Asotiation of Hematology</description>
  </link>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>July 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2009</study_first_posted>
  <last_update_submitted>May 7, 2015</last_update_submitted>
  <last_update_submitted_qc>May 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia (ALL)</keyword>
  <keyword>Depocyte®</keyword>
  <keyword>Neuromeningeal relapse</keyword>
  <keyword>Between 16 and 30 years old</keyword>
  <keyword>Standard risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

